Acrylic Acid And Derivatives Patents (Class 424/487)
  • Patent number: 10668019
    Abstract: The present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof. In particular, the present invention relates to an improved active or inactive pharmaceutical ingredient-polymer composition and process of preparation thereof wherein the monomer encapsulates particles of active or inactive pharmaceutical ingredient at molecular level and with controlled polymerization process the monomer turns into the said polymer coat over the said active or inactive pharmaceutical ingredient that facilitates the disclosed invention to be completed a single step process.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: June 2, 2020
    Inventor: Kirit Patel
  • Patent number: 10655000
    Abstract: An organic/inorganic composite hydrogel can be prepared only through mixing at a room temperature and that has high modulus of elasticity and a self-supporting property that allows a shape to be maintained in water, and a method produces the hydrogel. A hydrogel forming composition that is capable of forming a hydrogel having a self-supporting property, includes: a water-soluble organic polymer having an organic acid structure, an organic acid salt structure, or an organic acid anion structure; a silicate salt; a dispersant for the silicate salt; and a compound having or generating divalent or higher valent positive charge; a hydrogel formed of the composition, and a method for producing the hydrogel.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: May 19, 2020
    Assignees: NISSAN CHEMICAL INDUSTRIES, LTD., RIKEN
    Inventors: Yoshihiro Kudo, Taichi Nakazawa, Takuzo Aida, Yasuhiro Ishida, Shingo Tamesue, Masataka Ohtani
  • Patent number: 10640580
    Abstract: Provided is a method of suspension polymerization comprising (I) providing a composition comprising droplets distributed in an aqueous medium, wherein the droplets comprise one or more boronic acids, one or more monomers, and one or more initiators, and wherein the aqueous medium comprises polyvinyl alcohol; wherein the one or more boronic acids are present in an amount of 0.002% or more, by weight based on the weight of the droplets, and (II) stressing the composition so that the initiator initiates polymerization of the monomer.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 5, 2020
    Assignee: DDP SPECIALTY ELECTRONIC MATERIALS US 8, LLC
    Inventors: Andrew M. Savo, Matthew D. Reichert, John David Finch, Lester H. Mcintosh, III, Robert Johnson, Alfred K. Schultz
  • Patent number: 10633578
    Abstract: A method of treating a subterranean formation including suspending proppant particulates in a treatment fluid, wherein the proppant particles include a coating comprising a salt-tolerant, water-swellable polymer, and the treatment fluid includes at least one fluid consisting of fresh water, salt water, seawater, brine, an aqueous salt solution, and combinations thereof; and introducing the treatment fluid containing the settling retardant proppant particulates into the subterranean formation. A composite proppant particle includes a proppant substrate and a salt tolerant polymeric layer deposited on the proppant substrate.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: April 28, 2020
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Yuntao Thomas Hu, Travis Hope Larsen, Corneliu Stanciu, Ajish Potty
  • Patent number: 10471175
    Abstract: A method for preparing a composition for external treatment of wounds includes charging at least 90% of the oxygen binding sites of hemoglobin with carbon monoxide during or after isolation from its natural environment. The method further includes adding at least one further ingredient selected from the group consisting of electrolyte(s), preservative(s), stabilizer(s), anti-flocculant(s), anticoagulant(s), pH buffering agent(s), solvent(s), antioxidant(s), film-forming agent(s) and crosslinking agent(s). The method can further include packaging the composition, such as in an aerosol can.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 12, 2019
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventors: Michael Sander, Harald Potzschke
  • Patent number: 10357766
    Abstract: Disclosed are composite materials and methods of making them. The composite materials comprise a support member and a cross-linked gel, wherein the cross-linked gel is a polymer synthesized by thiol-ene or thiol-yne polymerization and cross-linking. The cross-linked gel may be functionalized by a thiol-ene or thiol-yne grafting reaction, either simultaneously with the polymerization or as the second step in a two-step procedure. The composite materials are useful as chromatographic separation media.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: July 23, 2019
    Assignee: Natrix Separations Inc.
    Inventors: Amro Ragheb, Gary Skarja
  • Patent number: 10307382
    Abstract: The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: June 4, 2019
    Assignee: Photonamic GmbH & Co. KG
    Inventors: Tobias Jung, Michael Horstmann, Gerd Hoffmann
  • Patent number: 10278963
    Abstract: A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: May 7, 2019
    Assignee: LUPIN LIMITED
    Inventors: Dhananjay Sadashiv Bakhle, Chirag Anilkumar Shah, Snehal Ameet Gadve, Neha Sharma, Sajeev Chandran, Ashish Ashokrao Deshmukh
  • Patent number: 10278922
    Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 7, 2019
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Daniel G. Anderson, Robert S. Langer, Tram T. Dang
  • Patent number: 10272038
    Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Intelgenx Corp.
    Inventors: Rodolphe Obeid, Nadine Paiement
  • Patent number: 10240083
    Abstract: An aqueous fluid, possibly a wellbore fracturing fluid, comprises an aqueous solution or dispersion of a first polymer, which may be polysaccharide, as a thickener and a cross linking agent to enhance the viscosity of the fluid by crosslinking the first polymer, wherein the crosslinking agent is a second polymer comprising at least one polymer chain with phenyl boronate groups distributed along the polymer chain and the phenyl boronic acid groups have nitrogen attached to the phenyl group at a position which is meta relative to the boronate group.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: March 26, 2019
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventors: Gary John Tustin, Valerie Lafitte, Bruno Drochon
  • Patent number: 10113050
    Abstract: A powdery or granulated composition, containing: (a) a copolymer containing, in polymerized form, a C1- to C4-alkyl ester of acrylic or methacrylic acid and an alkyl(meth)acrylate monomer containing a tertiary amino group in an alkyl radical; (b) 0.5 to 10% by weight based on (a) of a dicarboxylic acid having 3 to 10 carbon atoms; and (c) 5 to 20% by weight based on (a) of a fatty monocarboxylic acid having 8 to 18 carbon atoms, where the composition contains at least by 30% by weight of (a), (b), and (c).
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: October 30, 2018
    Assignee: Evonik Roehm GmbH
    Inventors: Erna Roth, Ruediger Alexowsky, Hans-Ulrich Petereit, Christian Meier
  • Patent number: 10076494
    Abstract: Described herein are stable orally disintegrating tablets containing a proton pump inhibitor, methods for making the same, and methods for treating subjects in need thereof. In particular, the orally disintegrating tablets are composed of a plurality of coated units admixed with a disintegrant that demonstrate decreased friability and increased hardness.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 18, 2018
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Victor Pevzner, Sheera Moses-Heller
  • Patent number: 10029031
    Abstract: A bone void filler material is provided that is configured for sustained release of a therapeutic agent. The bone void filler material comprises a biodegradable matrix having ceramic particles and cement beads disposed within the matrix, the cement beads loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: July 24, 2018
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: William F. McKay
  • Patent number: 9962381
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 8, 2018
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Patent number: 9901662
    Abstract: An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: February 27, 2018
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Tatsuru Fukuda, Hirofumi Tamura
  • Patent number: 9895466
    Abstract: The invention relates to a novel antibiotic delivery vehicle for impregnating bone cement wherein said vehicle is an antibiotic encapsulated liposome having a block co-polymer on its surface; a method for the manufacture of a bone cement impregnated with antibiotic or a mixture of antibiotics using said vehicle; and also a novel bone cement made therewith and/or thereby.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: February 20, 2018
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Stephen Denyer, Samuel Evans, Wayne Ayre, James Birchall
  • Patent number: 9867781
    Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: January 16, 2018
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Daniel G. Anderson, Robert S. Langer, Tram T. Dang
  • Patent number: 9838807
    Abstract: A screw-shaped anchoring fixture for anchoring a prosthesis in the skull bone. The anchoring fixture comprises a main body configured to be implanted into the bone and a flange configured to function as a stop to prevent the main body from completely penetrating through the bone. The main body comprises a distal tapered apical portion, a first portion, and a second portion. The inner diameter of the second portion is greater than the inner diameter of the first portion. The method for inserting the anchoring fixture includes providing the anchoring fixture, drilling a hole, and inserting the anchoring fixture into the hole until the flange contacts the skull bone, wherein the hole has a diameter that is greater than the inner diameter of the first portion and less than the outer diameter of the second portion.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: December 5, 2017
    Assignee: Cochlear Limited
    Inventors: Lars Jinton, Erik Holgersson, Peter Elmberg
  • Patent number: 9827207
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: November 28, 2017
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Patent number: 9738730
    Abstract: The present invention provides a means for improving water-solubility of polysaccharide. A polysaccharide powder according to the present invention has a particle size distribution in which 30 vol % or more of the total volume of the powder has particle sizes of 200 to 750 ?m.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: August 22, 2017
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Risa Yuki, Taishi Niimi
  • Patent number: 9733254
    Abstract: Methods and apparatus for the in vitro modelling of changes that occur on administration of a drug formulation are described, in particular for studying the changes that take place on administration of protein or peptide drug formulations by subcutaneous injection.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: August 15, 2017
    Assignee: The University of Bath
    Inventors: Randall Jay Mrsny, Hanne Maarit Kinnunen
  • Patent number: 9668970
    Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: June 6, 2017
    Assignee: IntelGenx Corp.
    Inventors: Rodolphe Obeid, Nadine Paiement
  • Patent number: 9649385
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: May 16, 2017
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Patent number: 9623044
    Abstract: The present invention relates to chitosan hydrogel microparticles of a median size d50 comprised between 1 and 500 ?m (obtained from a number distribution), the chitosan having a degree of acetylation of less than equal to 20% and its concentration in the hydrogel being comprised between 0.25 and 5% by weight based on a total weight of the hydrogel, for use in neuron regeneration and/or in the repair of the nervous system, advantageously of the central nervous system, and/or in the grafting of neurons and/or in the treatment of neurodegenerative diseases and/or in the treatment of paralyses. It also relates to an implant comprising an aqueous suspension of microparticles mixed with Schwann cells and/or stem cells and/or trophic factors.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: April 18, 2017
    Assignees: UNIVERSITE CLAUDE BERNARD LYON I, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, UNIVERSITE JEAN MONNET, SAINT ETIENNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Fatiha Nothias, Sylvia Soares, Laurent David, Alexandra Montembault
  • Patent number: 9504754
    Abstract: Methods and materials relating to a medicament preparation comprising a curcuminoid component and a euradit component provided as a curcuminoid-eudragit complex, which enhance the bioavailability of the curcumin component and are useful for the treatment of various diseases including cancer, neurodegeneration, inflammation, and immunodeficiency. In some aspects, the curcuminoid component comprises curcumin to prepare a curcumin-eudragit complex and a medicament comprising curcumin-eudragit complexes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 29, 2016
    Assignee: South Dakota Board of Regents
    Inventors: Hemachand Tummala, Sunny Kumar
  • Patent number: 9469726
    Abstract: Water soluble biodegradable polymers were prepared by an organoacid catalyzed ring opening polymerization (ROP) of a cyclic carbonate monomer bearing an active ester side chain. The initial polymer comprising an active ester side chain was treated with an amino-alcohol, which transformed the active ester groups to N-substituted amide groups bearing mono-hydroxy alkyl groups and/or dihydroxy alkyl groups, thereby forming the water soluble polymers. The water-soluble polymers are non-toxic and exhibit stealth properties in buffered serum solution.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: October 18, 2016
    Assignees: International Business Machines Corporation, Agency For Science, Technology And Research
    Inventors: Daniel J. Coady, Amanda C. Engler, James L. Hedrick, Xiyu Ke, Yi Yan Yang
  • Patent number: 9446024
    Abstract: The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: September 20, 2016
    Assignees: Université Laval, Mission Pharmacal Company
    Inventors: Michel G. Bergeron, Jian Gao, Rabeea F. Omar, Mary Ann Walter
  • Patent number: 9422387
    Abstract: A composition includes a responsive block copolymer, the responsive block copolymer including at least one block A that is a triggerable copolymer, the triggerable copolymer including at least one lower critical solution temperature monomer and at least one charged monomer, wherein the triggerable copolymer block A is a dual trigger block configured to trigger on temperature and ionic strength, and wherein the responsive block copolymer micellizes or gels at a temperature between 28° C. and 37° C. and a salt concentration of about 0.9 wt %.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: August 23, 2016
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: William Clayton Bunyard, Timothy E Long, Adam E. Smith, Shijing Cheng, Sean T. Hemp
  • Patent number: 9393278
    Abstract: A herbal composition for wound healing is disclosed. The herbal composition comprises an extract of honeysuckle and an extract of mint in a weight ration of 1:2 to 2:1. The herbal composition further comprises a medical acceptable excipient.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: July 19, 2016
    Assignee: HAN SHENG BIOTECH CO., LTD.
    Inventors: Shorong-Shii Liou, I-Min Liu, Wei-Cheng Chen, Ren-Jye Wang
  • Patent number: 9387174
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: July 12, 2016
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 9333150
    Abstract: The invention relates to a dental restorative material on the basis of at least one compound of Formula I A-[X-Q-(Y-CG)n]m?? Formula I, wherein CG represents in each case independently an azide group N3 or an alkyne group selected from the group consisting of —CR1R2—C?CH, with the proviso that the dental restorative material comprises at least one compound of Formula I comprising an azide group and at least one compound of Formula I comprising an alkyne group. The invention also relates to the use of the dental restorative materials according to the invention for preparing dental composites, preferably composite blanks, which are suitable in particular for mechanical processing by means of computer-aided processing techniques such as milling and grinding processes, and which are suitable above all for preparing dental restoration materials such as inlays, onlays, crowns, bridges or veneering materials.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: May 10, 2016
    Assignee: Ivoclar Vivadent AG
    Inventors: Norbert Moszner, Peter Burtscher, Urs Karl Fischer, Thomas Hirt, Ulrich S. Schubert, Martin Hager, Bobby Happ, Benedict Sandmann
  • Patent number: 9284416
    Abstract: The present invention provides a process for converting a solid (meth)acrylate copolymer into a dispersed form by preparing an aqueous dispersion comprising the components (a) a (meth)acrylate copolymer which is composed of free-radical polymerized methyl methacrylate, ethylacrylate and a salt of 2-trimethylammoniumethyl methacrylate, present in solid form as a powder or as a granulate, (b) up to 50% by weight calculated on the (meth)acrylate copolymer (a) of a dispersing agent selected from the groups of (b) i) plasticizers in combination with emulsifiers and/or (b) ii) pharmaceutically acceptable carbohydrates having 6 to 18 carbon atoms with a functional group and (c) water by mixing the components (a), (b) and (c) to give a suspension which becomes an aqueous dispersion during the conversion of the solid (meth)acrylate copolymer into the dispersed form, characterized in that, the (meth)acrylate copolymer is converted into the dispersed form by means of the presence of the dispersing agent at a temperature
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: March 15, 2016
    Assignee: Evonik Roehm GmbH
    Inventors: Erna Roth, Ruediger Alexowsky, Hans-Ulrich Petereit, Kathrin Nollenberger, Christian Meier
  • Patent number: 9192609
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: November 24, 2015
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Patent number: 9161914
    Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: October 20, 2015
    Assignee: Merz Pharmaceuticals, LLC
    Inventors: Bhushan Hardas, Donna Dalton
  • Patent number: 9056137
    Abstract: The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 16, 2015
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventor: Stephen I-Hong Hsu
  • Patent number: 9023382
    Abstract: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary polymer. The medicament carrier composition is used to form a film that is also substantially free of cellulose. The film has a consistent thickness and size, and an increased flexibility and increased moisture resistance due to the polyvinylpyrrolidone. The medicament carrier composition is also used in a method of forming the film. The method includes the steps of providing the medicament and the polymer component. The method also includes the step of combining the polymer component and the medicament to form the medicament carrier composition. The method further includes the step of drying the medicament carrier composition to form the film.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: May 5, 2015
    Assignee: BASF Corporation
    Inventors: Shaukat Ali, Anisul Quadir
  • Patent number: 9017723
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 28, 2015
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Jianye Wen, Richard Hamlin
  • Patent number: 9012424
    Abstract: The present invention relates to a polymer according to Formulas (1) or (2): The present invention further relates to nanogels and nanoparticles made of a polymer according to general Formulas (1) and (2). The nanogels may comprise a biologically active component such as siRNA, miRNA, DNA, an (oligo)peptide or a proteins.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: April 21, 2015
    Assignee: 20MED Therapeutics B.V.
    Inventors: Johannes Franciscus Joseph Engbersen, Arkadi Vladimirovich Zinchenko
  • Publication number: 20150098997
    Abstract: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
  • Patent number: 8992899
    Abstract: Disclosed herein are cosmetic compositions comprising at least one film-forming polymer, at least one silicone elastomer blend, and at least one wax. Also disclosed herein are methods for making up and/or enhancing the appearance of a keratinous substrate comprising applying said composition to the keratinous substrate.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: March 31, 2015
    Assignee: L'Oreal
    Inventors: Kavita Patel, Angeles Fonolla-Moreno, Naoto Sugimoto
  • Patent number: 8986735
    Abstract: A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer and a taste masked ketoprofen active. Also provided are methods for preparing the solid dosage form and for using the solid dosage to administer an effective dosage of an active agent, such as ketoprofen, into the oral cavity for absorption.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: March 24, 2015
    Assignee: Novartis AG
    Inventors: Alexander M Schobel, Shyam S Vangala
  • Patent number: 8968783
    Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 3, 2015
    Assignee: Covidien LP
    Inventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla
  • Patent number: 8957008
    Abstract: Agent for obtaining a stable aqueous composition comprising an association: of a polymer constituted by: at least one A monomer of acrylic acid and/or methacrylic acid and/or any of their salts, at least one B monomer of alkyl acrylate and/or methacrylate, and At least one crosslinking D monomer, and with at least one C compound corresponding to the following formulae (I): R1-O-[(EO)n(PO)n?(BO)n?]—Z??(I) in which: R1 represents an ethyl, isopropyl or sec-butyl radical, [(EO)n(PO)n?(BO)n?] represents a polyalkoxylated chain constituted of alkoxylated units, distributed into blocks, alternatively or statistically, chosen from among EO ethoxylated units, PO propoxylated units and BO butoxylated units, representing, independently from each other, 0 or a whole number between 1 and 150, the sum of n, n? and n? not being null, and Z represents a fatty chain, linear or branched, of at least 16 carbon atoms.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 17, 2015
    Assignee: Coatex
    Inventors: Renaud Souzy, Yves Kensicher, Olivier Guerret
  • Patent number: 8940318
    Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 27, 2015
    Assignees: Seed Co., Ltd., Senju Pharmaceutical Co., Ltd.
    Inventors: Takao Sato, Toru Matsunaga, Aya Ichinokawa, Osamu Sakai
  • Patent number: 8927023
    Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: January 6, 2015
    Assignee: Fresenius Kabi Oncology Limited
    Inventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
  • Patent number: 8916683
    Abstract: Described herein are block copolymer conjugates that form double-network hydrogels under appropriate conditions. The conjugates comprise a block of polymer end-group, a block of self-associating peptide or protein, and flexible linkers between the two. Hydrogels comprising the conjugates have the mechanical properties, including elastic modulus and fracture toughness, required for load-bearing applications, while maintaining desirable shear-thinning properties, for example, for injectability.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: December 23, 2014
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley D. Olsen, Matthew J. Glassman, Jacqueline Chan
  • Patent number: 8907153
    Abstract: The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: December 9, 2014
    Assignee: Nuvo Research Inc.
    Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
  • Patent number: 8883212
    Abstract: The invention provides novel dental film-forming compositions, comprising i. an acrylate/octylacrylamide copolymer, ii. one or more alkyl cellulose ethers, and iii. a solvent, and optionally further comprising whitening materials and/or active agents, together with method for using the same.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Shyamala Pillai, Guofeng Xu
  • Patent number: 8871818
    Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: October 28, 2014
    Assignees: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku